Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Refer a friend or colleague
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

Updated list of "Drugs to avoid, in the name of better patient care" is published by independent French journal Prescrire The independent French medical journal Prescrire has published its annual review of "Drugs to avoid", identifying drugs that are clearly more harmful than beneficial. The full report will be published in English in the February 2020 issue of Prescrire International. 1 December 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Emicizumab (Hemlibra°) in haemophilia A. A first-choice preventive treatment for patients with factor VIII inhibitors FEATURED REVIEW Prescrire's editors have rated emicizumab prophylaxis in patients with haemophilia A in whom factor VIII is no longer effective due to the development of factor VIII inhibitors "a real advance". Reduced incidence of bleeding and greater convenience should be weighed against the lack of long-term data, the lack of evaluation in certain clinical situations, and the risk of thrombosis. Full review (2 pages) available for download by subscribers. 1 December 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the December issue of Prescrire International: pertuzumab (Perjeta°) after surgery for some breast cancers at high risk of recurrence FREE DOWNLOAD Pertuzumab (Perjeta°) is a monoclonal antibody which has been authorised for use after surgery for some breast cancers. How do Prescrire's editors rate the drug's harm-benefit balance in this situation, in light of the most recent evidence? Full text available for free download. 1 December 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The Mediator° disaster: so much time wasted, so many lives destroyed The independent French medical journal Prescrire began asking questions about the appetite-suppressant drug Mediator° (benfluorex) in 1986, and called for its withdrawal some 12 years before the French authorities finally took action.  In our special online section, a recap of how the disaster unfolded, and the tragic consequences for victims. 1 December 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Diclofenac: a habit that needs changing Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), is routinely used, despite evidence of a greater risk of adverse cardiovascular events when compared with other NSAIDs such as ibuprofen or naproxen, whereas it offers no additional benefit. 1 December 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Anti-inflammatory drugs: risks for the kidneys even in young, healthy adults Taking nonsteroidal anti-inflammatory drugs (NSAIDs) presents risks of nephrotoxicity in young people during intense physical exercise, especially in hot weather. 1 December 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Sore throat: paracetamol is the best option Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to be somewhat more effective than paracetamol, but they expose patients to more serious side effects. 1 December 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Echinacea purpurea in the common cold • Colchicine and acute pericarditis • Antiepileptics and pregnancy: potential long-term effects in children • Persistent psychotic disorders and neuroleptics • Dapagliflozin in type 2 diabetes • Opioid marketing and prescribing... > Subscribe now 1 December 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The European Medicines Agency's independence is paramount: concrete alternatives to the fee-for-service system must be found  ADVANCING HEALTHCARE POLICY  Prescrire's response to a public consultation on the revision of the EMA fee system, Prescrire emphasises that EMA needs to be weaned off a fee-for-service relationship with pharmaceutical companies and funded through public funding from the European Union. 1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Faces of Mediator", a new book published by Prescrire It was after seeing the French film "La Fille de Brest", an adaptation of the book by pulmonologist and whistle-blower Irène Frachon, that the photographer Marc Dantan first got the idea of taking portraits of the victims of Mediator° (benfluorex), in the hope that "bringing faces into the light could perhaps raise awareness of the silent suffering". That was the beginning of this book, which presents in 208 pages some 180 photographs, along with a foreword by Irène Frachon, a summary of the history of the Mediator° disaster, and an afterword by Prescrire. Texts in French and English. 1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 December 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2019", new from the editors of Prescrire International  NEW: FREE SPECIAL EDITION  Check out this brand new sampling of texts selected by our editors to introduce you to Prescrire International, a wholly independent monthly journal, written by and for healthcare professionals 28 August 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 September 2018

• Sitemap |
• Terms of use |
• Contact
• |Top of page